Moderna Stock Performance
| MRNA Stock | USD 34.15 0.14 0.41% |
On a scale of 0 to 100, Moderna holds a performance score of 8. The company secures a Beta (Market Risk) of 2.54, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Moderna will likely underperform. Please check Moderna's maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to make a quick decision on whether Moderna's current price movements will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Moderna are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Moderna sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.41 | Five Day Return 8.31 | Year To Date Return (18.69) | Ten Year Return 83.6 | All Time Return 83.6 |
1 | mRNA Cancer Vaccines Clinical Trials Future Market Outlook 2025 Personalized mRNA Cancer Vaccines Revolutionize Oncology with Neoantigen-Driven Immunotherapy | 07/07/2025 |
2 | Why Moderna Stock Is Up Today | 07/10/2025 |
3 | Moderna Remains Most Shorted Stock in Health Care Sector | 07/14/2025 |
4 | Feast Day of Saint Marina | 07/16/2025 |
5 | Las Vegas Sands breaks ground on the 8B high-profile expansion of the Marina Bay Sands | 07/17/2025 |
6 | Moderna, Inc.s Price Is Right But Growth Is Lacking After Shares Rocket 26 | 07/18/2025 |
7 | FDA Approved Moderna COVID Shot For Kids Behind Kennedys Back - Two HHS Aides Fired | 07/22/2025 |
8 | Is Moderna Inc Set to Underperform Analyzing the Factors Limiting Growth | 07/23/2025 |
9 | Biotech Is Booming, and This Undervalued REIT Stands to Gain | 07/25/2025 |
| Begin Period Cash Flow | 2.9 B | |
| Total Cashflows From Investing Activities | 1.9 B |
Moderna Relative Risk vs. Return Landscape
If you would invest 2,746 in Moderna on April 28, 2025 and sell it today you would earn a total of 669.00 from holding Moderna or generate 24.36% return on investment over 90 days. Moderna is currently generating 0.4137% in daily expected returns and assumes 3.6746% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Moderna, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Moderna Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moderna's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moderna, and traders can use it to determine the average amount a Moderna's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MRNA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.67 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Moderna is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moderna by adding it to a well-diversified portfolio.
Moderna Fundamentals Growth
Moderna Stock prices reflect investors' perceptions of the future prospects and financial health of Moderna, and Moderna fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moderna Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.06) % | ||||
| Operating Margin | (9.72) % | ||||
| Current Valuation | 7.92 B | ||||
| Shares Outstanding | 386.74 M | ||||
| Price To Earning | 6.37 X | ||||
| Price To Book | 1.31 X | ||||
| Price To Sales | 4.16 X | ||||
| Revenue | 3.24 B | ||||
| Gross Profit | (2.62 B) | ||||
| EBITDA | (3.39 B) | ||||
| Net Income | (3.56 B) | ||||
| Cash And Equivalents | 8.35 B | ||||
| Cash Per Share | 21.73 X | ||||
| Total Debt | 747 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 2.10 X | ||||
| Book Value Per Share | 26.01 X | ||||
| Cash Flow From Operations | (3 B) | ||||
| Earnings Per Share | (8.73) X | ||||
| Market Capitalization | 13.21 B | ||||
| Total Asset | 14.14 B | ||||
| Retained Earnings | 10.04 B | ||||
| Working Capital | 5.89 B | ||||
| Current Asset | 850 K | ||||
| Current Liabilities | 2.44 M | ||||
About Moderna Performance
By analyzing Moderna's fundamental ratios, stakeholders can gain valuable insights into Moderna's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Moderna has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moderna has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 29.17 | 27.71 | |
| Return On Tangible Assets | (0.25) | (0.24) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.25) | (0.24) | |
| Return On Equity | (0.33) | (0.31) |
Things to note about Moderna performance evaluation
Checking the ongoing alerts about Moderna for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moderna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moderna had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.62 B). | |
| Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73. | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from fool.com: Biotech Is Booming, and This Undervalued REIT Stands to Gain |
- Analyzing Moderna's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moderna's stock is overvalued or undervalued compared to its peers.
- Examining Moderna's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moderna's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moderna's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moderna's stock. These opinions can provide insight into Moderna's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |